Arbutus Biopharma Corporation filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer with common shares without par value and a business focused on chronic hepatitis B therapeutics and lipid nanoparticle intellectual property. Form 8-K reports cover financial results, FDA Fast Track designation for imdusiran, material agreements, court orders, patent proceedings involving LNP delivery technology, and licensing or settlement matters with Genevant Sciences.
The company’s proxy materials describe annual shareholder meeting matters, board governance, executive compensation, voting procedures, and related corporate approvals. Its regulatory disclosures also connect clinical and regulatory updates for imdusiran with capital-structure, risk, intellectual-property, and operating-result reporting.
Arbutus Biopharma reported a sharp improvement in results for the six months ended June 30, 2026, driven by litigation-related license income. Total revenue was $180.1 million, up from $12.5 million a year earlier, primarily from $179.4 million of license revenue from Genevant, which includes Arbutus’ $178.4 million share of a $950.0 million noncontingent settlement payment from Moderna.
Operating expenses fell to $17.2 million from $36.7 million, reflecting prior restructuring and lower R&D. Arbutus generated net income of $164.6 million versus a $22.0 million loss in the prior-year period, although it recorded a $5.1 million net loss in the second quarter alone as settlement revenue was recognized earlier in the year. At June 30, 2026, the company held $92.6 million in cash, cash equivalents and short-term marketable securities with no debt, and also received the $178.4 million cash settlement on July 8, 2026. Management states it has sufficient resources to fund operations for at least the next 12 months while advancing hepatitis B programs, including imdusiran, which received FDA Fast Track designation, and AB‑101.
Arbutus Biopharma reported second quarter 2026 revenue of $1.0 million, down sharply from $10.7 million a year earlier, and a net loss of $5.1 million versus net income of $2.5 million in the prior-year quarter, driven largely by the absence of one-time deferred revenue recognized in 2025.
Despite the quarterly loss, Arbutus highlighted a significantly stronger balance sheet. As of June 30, 2026, it held $92.6 million in cash, cash equivalents and marketable securities and recorded a $179.4 million receivable from its Genevant license, reflecting its share of a $950 million global settlement with Moderna, including a $178.4 million noncontingent payment received in July and a further $1.3 billion potential contingent payment tied to appellate outcomes. The company stated it expects, subject to board approval, to return up to approximately $230 million to shareholders beginning in the third quarter of 2026 through possible share repurchases. Research and development expenses fell to $2.9 million from $5.5 million due to prior restructuring, while general and administrative costs rose to $3.9 million. Arbutus also reported FDA Fast Track designation and Phase 2b trial design alignment for its HBV candidate imdusiran and disclosed new international patent enforcement lawsuits filed with Genevant against Pfizer and BioNTech relating to lipid nanoparticle technology.
Arbutus Biopharma detailed several outcomes from its mRNA patent disputes. A March 2026 settlement with Moderna generated a $950 million noncontingent lump sum to Arbutus and Genevant, of which Arbutus received about $178 million (including reimbursed litigation costs), and provides for a potential contingent payment of up to $1.3 billion. Arbutus also terminated a prior RSV-related sharing agreement with Genevant in exchange for a $1.0 million termination fee.
The board approved one-time litigation-related cash bonuses for the CEO and for the CFO, whose bonus equals 0.25% of proceeds tied to the Moderna settlement. Arbutus and Genevant filed three international patent lawsuits against Pfizer/BioNTech over lipid nanoparticle technology, seeking monetary relief and injunctions. Arbutus expects to return capital to shareholders through repurchases of up to approximately $230 million of common shares after an anticipated dividend from its approximately 16% equity stake in Genevant’s parent, though any repurchase remains subject to board approval and may not occur.
Arbutus Biopharma Corp director Roger Sawhney received a fully vested stock option grant covering 78,800 common shares. The option was granted at an exercise price of $4.24 per share, matching the closing price of the company’s common shares on Nasdaq on the grant date.
The option is immediately exercisable and expires on June 8, 2036. This transaction reflects an equity-based compensation award and does not involve any open-market purchase or sale of Arbutus Biopharma shares.
Arbutus Biopharma director Robert A. Beardsley was granted stock options to acquire 78,800 common shares. The options have an exercise price of $4.24 per share, are fully vested and exercisable as of the grant date, and expire on June 8, 2036. This is a compensation-related award, not an open-market purchase or sale.
Arbutus Biopharma Corporation reported results from its 2026 Annual General and Special Meeting of Shareholders. Shareholders approved the new 2026 Omnibus Share and Incentive Plan, which authorizes issuance of an aggregate 16,300,000 common shares to support future equity-based compensation.
All director nominees were elected with strong majorities. Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Arbutus Biopharma Corporation: Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi report beneficial ownership of 18,557,543 common shares (9.4%) as of March 31, 2026. The shares are held by Two Seas Global (Master) Fund LP (13,904,953) and Two Seas LNP Opportunities (Master) Fund LP (4,652,590). The percent is calculated on 196,947,757 common shares outstanding as of March 31, 2026, per the issuer's Form 10-Q. The Reporting Persons state they have sole voting and sole dispositive power over the reported shares.
Arbutus Biopharma reported Q1 2026 revenue of $179.1M, up sharply due to recognizing $178.7M in license revenue tied to Genevant’s settlement with Moderna. This drove net income of $169.7M, compared with a loss in the prior-year quarter.
Total assets rose to $277.2M, including a $178.7M receivable from the noncontingent $950.0M Moderna settlement, while cash, cash equivalents and marketable securities were $95.2M with no debt. The company continues HBV programs for imdusiran and AB‑101 and is evaluating a potential return of capital after receiving its settlement share.
The FDA granted Fast Track designation to imdusiran for chronic hepatitis B, and Arbutus retains global rights to this RNAi candidate after ending its Qilu partnership. Litigation against Pfizer/BioNTech over LNP technology remains ongoing, and a separate contingent payment of up to $1.3B from Moderna depends on the outcome of a limited appeal.
Arbutus Biopharma reported a dramatic turnaround in the first quarter of 2026 driven by a major litigation settlement. Total revenue surged to $179.1 million, largely from $178.7 million of license revenue from Genevant tied to the Noncontingent Settlement Payment under its settlement with Moderna. This shift turned last year’s loss into net income of $169.7 million, compared with a net loss of $24.5 million in the prior-year quarter.
Cash, cash equivalents and marketable securities were $95.2 million as of March 31, 2026, modestly higher than at year-end. Research and development expenses fell to $4.1 million, reflecting workforce reductions, discontinued in-house research and lower clinical trial costs, while restructuring costs dropped to zero. The company also highlighted that the FDA granted Fast Track designation to its HBV RNAi therapeutic imdusiran, which may facilitate development and expedite review for chronic hepatitis B.
Whitefort Capital and related parties filed Amendment No. 4 to their Schedule 13D on Arbutus Biopharma Corp, reporting a significant ownership position. Whitefort Capital Master Fund directly owns 15,794,261 common shares, which is about 8.0% of Arbutus’s 196,939,679 shares outstanding as of March 30, 2026. The filing notes that these shares were acquired for an aggregate purchase price of approximately $41,324,734, funded from the fund’s working capital.
Various Whitefort entities and principals David Salanic and Joseph Kaplan may be deemed to share beneficial ownership of the same 15,794,261 shares through their roles as general partners and investment managers, though they expressly disclaim ownership of securities they do not directly hold. The filing also discloses a cash-settled total return swap between Whitefort Master Fund and Nomura Global Financial Products Inc. referencing 3,500,000 notional shares, or about 1.8% of outstanding shares, with a reference price of $4.2800 and maturity on October 29, 2029. Including these subject shares on an economic basis, Whitefort Master Fund’s total economic exposure is 19,294,261 shares, or roughly 9.8% of Arbutus’s outstanding stock, while they disclaim beneficial ownership and voting or dispositive power over the swap reference shares.